Navigation Links
MDA supports Duchenne muscular dystrophy research by University of Nevada School of Medicine
Date:8/22/2012

RENO, Nev. A novel treatment in development at the University of Nevada School of Medicine for the most common form of muscular dystrophy is advancing towards human trials with a $308,000 boost from the Muscular Dystrophy Association.

The grant will be used to expand successful research by Associate Professor of Pharmacology Dean Burkin that has shown his laminin-111 protein therapy prevents the onset of the devastating neuromuscular disease in mouse models.

"The early results for laminin-111 as a therapeutic agent for (Duchenne muscular dystrophy) are really exciting," Sanjay Bidichandani, MDA vice president of research, said. "We are eager to see this research go forward."

Duchenne muscular dystrophy is a lethal genetic disease that affects one in 3,500 newborn boys and is caused by mutations in the gene encoding dystrophin. There is no effective treatment or cure.

At the time of diagnosis, DMD patients usually have developed significant muscle disease. The three-year grant will help determine if Burkin's therapy is effective at preventing or reversing disease progression after onset.

"What we aim to discover now is if this therapy is effective at preventing or reversing disease progression after it has already started," he said. "First we will determine if laminin-111 prevents muscle damage after disease onset, preserves muscle function and improves survival of mouse models of DMD. Second, we will determine if laminin-111 prevents cardiomyopathy in mouse models of DMD.

"Finally, in collaboration with researchers at Texas A&M, we will determine if a human version of the protein prevents muscle disease in other animals afflicted with the disease. Results from these studies will pave the way towards developing human recombinant laminin-111 protein as a novel therapeutic for DMD."

Demonstrating that the human version has efficacy in animals with DMD will move this therapy closer to a Food and
'/>"/>

Contact: Mike Wolterbeek
mwolterbeek@unr.edu
University of Nevada, Reno
Source:Eurekalert  

Page: 1 2 3

Related biology news :

1. Study jointly led by UCSB researcher supports theory of extraterrestrial impact
2. NOAA science supports New Yorks offshore energy planning
3. Leading childhood asthma group supports federal asthma action plan to reduce disparities
4. New compound holds promise for treating Duchenne MD, other inherited diseases
5. New genetically engineered mice aid understanding of incurable neuromuscular disease
6. Real-life spider men using protein found in venom to develop muscular dystrophy treatment
7. Low oxygen levels may decrease life-saving protein in spinal muscular atrophy
8. Study by UC Santa Barbara researchers suggests that bacteria communicate by touch
9. Research reveals first evidence of hunting by prehistoric Ohioans
10. Diabetes Research Institute develops oxygen-generating biomaterial
11. APS issues new policy requiring identification of sex or gender in reporting scientific research
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
MDA supports Duchenne muscular dystrophy research by University of Nevada School of Medicine
(Date:9/18/2014)... roaches of the fish world, are the ideal animal ... shape. They,ve moved from the ocean into tens of ... each time changing their skeleton to adapt to the ... populations of sticklebacks now have turned up one of ... a simple change in that gene,s regulation in a ...
(Date:9/18/2014)... protective tentacles of host anemones, but new research shows ... across the open ocean. Although the process of long-distance ... the first time that the high level exchange of ... Steve Simpson, Senior Lecturer in Marine Biology and Global ... the Australian Research Council Centre of Excellence for Coral ...
(Date:9/17/2014)... Institute for the Arts and Humanities has received a ... a two-year project, "The Boundaries of the Human in ... will support a wide-ranging series of events aimed at ... One involves artists and researchers who are exploring the ... idea of humanism, and the other involves the increasingly ...
Breaking Biology News(10 mins):Counting fish teeth reveals regulatory DNA changes behind rapid evolution, adaptation 2Counting fish teeth reveals regulatory DNA changes behind rapid evolution, adaptation 3Expedition finds Nemo can travel great distances to connect populations 2Expedition finds Nemo can travel great distances to connect populations 3Mellon Foundation awards grant for major project in the humanities and sciences 2
... University of Florida study following the evolution of lice ... ago, a technology which enabled them to successfully migrate ... associate curator of mammals at the Florida Museum of ... modern humans to better understand human evolution and migration ...
... Calif.) Calling the results "extremely surprising," researchers from ... University report that methane gas concentrations in the Gulf ... months after a massive release occurred following the Deepwater ... study, led by oceanographers John Kessler of Texas A&M ...
... a significant step forward in understanding the atmosphere,s ... some other gases, except carbon dioxide. The issue ... studies suggesting the self-cleaning power of the atmosphere ... others suggest greater stability. And what researchers are ...
Cached Biology News:UF study of lice DNA shows humans first wore clothes 170,000 years ago 2UF study of lice DNA shows humans first wore clothes 170,000 years ago 3UCSB, Texas A&M scientists find methane gas concentrations have returned to near-normal levels 2NOAA-led team measures atmosphere's self-cleaning capacity 2NOAA-led team measures atmosphere's self-cleaning capacity 3
(Date:9/18/2014)... 2014  MEI Pharma, Inc. (Nasdaq: MEIP ), ... therapies for cancer, announced today that Daniel P. Gold ... BioCentury,s NewsMakers in the Biotech Industry conference on ... the Millennium Broadway Hotel & Conference Center in ... can be accessed at www.meipharma.com . A replay will ...
(Date:9/18/2014)... Pennsylvanie, 18 septembre 2014 Mapi, ... en 1974, a été depuis 40 ans ... évaluations cliniques traditionnelles par des évaluations recentrées ... sur les impacts économiques des traitements. ... A cours d,une récente conférence ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 SeqLL ... Sequencing (tSMS™) technology, announced today the closing of ... investment, led by Genomic Diagnostic Technologies, will increase ... diagnostic applications. , Founded in March 2013 by ... Bioinformatics Analyst at Helicos BioSciences, SeqLL has continued ...
(Date:9/18/2014)... to weight loss and diabetes prevention, could actually hasten ... they do it in a surprising way: by changing ... the substantial population of bacteria residing in our intestines. ... humans, were published today in Nature . Among ... Institute,s Immunology Department, who led this research together with ...
Breaking Biology Technology:MEI Pharma To Present At BioCentury's NewsMakers Conference 2MEI Pharma To Present At BioCentury's NewsMakers Conference 31974 - 2014 - Mapi fête ses 40 ans 2SeqLL Closes Series-A Funding Round for Expansion of Single Molecule Sequencing 2Gut bacteria, artificial sweeteners and glucose intolerance 2Gut bacteria, artificial sweeteners and glucose intolerance 3
... only once-daily inhaled corticosteroid inhaler ... approved for children as young as age 4, KENILWORTH, ... today that ASMANEX(R) TWISTHALER(R) 110,mcg (mometasone furoate inhalation powder) is ... treatment of asthma as,prophylactic therapy in patients four years of ...
... August 19 ChemAxon, a software,solutions provider for ... their cheminformatics toolkits, Marvin & JChem. As well ... IUPAC name import,support for OLE 2 format useful ... JChem is a software suite of application programming,interfaces ...
... microRNA Technology, Developed by Columbia University Medical Center, ... Clinical use Acquires CLIA-certified lab to Expedite Commercialization of its ... microRNA-based Tests, Expands Pipeline With Three Additional microRNA-based Cancer Tests in ... Development, REHOVOT, Israel and ...
Cached Biology Technology:Video: ASMANEX(R) TWISTHALER(R) 110 MCG (Mometasone Furoate Inhalation Powder) is Now Available Nationwide for the Maintenance Treatment of Asthma in Children Ages 4 to 11 2Video: ASMANEX(R) TWISTHALER(R) 110 MCG (Mometasone Furoate Inhalation Powder) is Now Available Nationwide for the Maintenance Treatment of Asthma in Children Ages 4 to 11 3Video: ASMANEX(R) TWISTHALER(R) 110 MCG (Mometasone Furoate Inhalation Powder) is Now Available Nationwide for the Maintenance Treatment of Asthma in Children Ages 4 to 11 4Video: ASMANEX(R) TWISTHALER(R) 110 MCG (Mometasone Furoate Inhalation Powder) is Now Available Nationwide for the Maintenance Treatment of Asthma in Children Ages 4 to 11 5Video: ASMANEX(R) TWISTHALER(R) 110 MCG (Mometasone Furoate Inhalation Powder) is Now Available Nationwide for the Maintenance Treatment of Asthma in Children Ages 4 to 11 6Video: ASMANEX(R) TWISTHALER(R) 110 MCG (Mometasone Furoate Inhalation Powder) is Now Available Nationwide for the Maintenance Treatment of Asthma in Children Ages 4 to 11 7Video: ASMANEX(R) TWISTHALER(R) 110 MCG (Mometasone Furoate Inhalation Powder) is Now Available Nationwide for the Maintenance Treatment of Asthma in Children Ages 4 to 11 8ChemAxon Launches Marvin and JChem Version 5.1; Name to Structure Generation, OLE 2 and JavaScript Integration 2Rosetta Genomics Reports Second Quarter 2008 Financial Results 2Rosetta Genomics Reports Second Quarter 2008 Financial Results 3Rosetta Genomics Reports Second Quarter 2008 Financial Results 4Rosetta Genomics Reports Second Quarter 2008 Financial Results 5Rosetta Genomics Reports Second Quarter 2008 Financial Results 6Rosetta Genomics Reports Second Quarter 2008 Financial Results 7Rosetta Genomics Reports Second Quarter 2008 Financial Results 8Rosetta Genomics Reports Second Quarter 2008 Financial Results 9Rosetta Genomics Reports Second Quarter 2008 Financial Results 10Rosetta Genomics Reports Second Quarter 2008 Financial Results 11Rosetta Genomics Reports Second Quarter 2008 Financial Results 12
Mouse monoclonal [3B6] to HSV1 + HSV2 ICP5 Major Capsid Protein ( Abpromise for all tested applications)....
Mouse monoclonal [SPM302] to BCAR1, prediluted ( Abpromise for all tested applications). entrezGeneID: 9564 SwissProtID: P56945...
...
p21 Ras Immunogen: Recombinant C-H-ras p21(val-12). Storage: 4 C...
Biology Products: